DE69735057D1 - Wasserlösliche paclitaxel-prodrogen - Google Patents

Wasserlösliche paclitaxel-prodrogen

Info

Publication number
DE69735057D1
DE69735057D1 DE69735057T DE69735057T DE69735057D1 DE 69735057 D1 DE69735057 D1 DE 69735057D1 DE 69735057 T DE69735057 T DE 69735057T DE 69735057 T DE69735057 T DE 69735057T DE 69735057 D1 DE69735057 D1 DE 69735057D1
Authority
DE
Germany
Prior art keywords
paclitaxel
water
tumors
poly
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735057T
Other languages
English (en)
Other versions
DE69735057T2 (de
Inventor
Chun Li
Sidney Wallace
Dong-Fang Yu
David J Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PG TXL Co LP
Original Assignee
PG TXL Co LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PG TXL Co LP filed Critical PG TXL Co LP
Application granted granted Critical
Publication of DE69735057D1 publication Critical patent/DE69735057D1/de
Publication of DE69735057T2 publication Critical patent/DE69735057T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DE69735057T 1996-03-12 1997-03-11 Wasserlösliche paclitaxel-prodrogen Expired - Lifetime DE69735057T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1318496P 1996-03-12 1996-03-12
US13184P 1996-03-12
PCT/US1997/003687 WO1997033552A1 (en) 1996-03-12 1997-03-11 Water soluble paclitaxel prodrugs

Publications (2)

Publication Number Publication Date
DE69735057D1 true DE69735057D1 (de) 2006-03-30
DE69735057T2 DE69735057T2 (de) 2006-08-31

Family

ID=21758713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735057T Expired - Lifetime DE69735057T2 (de) 1996-03-12 1997-03-11 Wasserlösliche paclitaxel-prodrogen

Country Status (23)

Country Link
US (2) US5977163A (de)
EP (2) EP0932399B1 (de)
JP (2) JP3737518B2 (de)
KR (1) KR100561788B1 (de)
CN (2) CN1304058C (de)
AT (1) ATE314843T1 (de)
AU (1) AU735900B2 (de)
BR (1) BR9710646A (de)
CA (1) CA2250295C (de)
CZ (1) CZ297979B6 (de)
DE (1) DE69735057T2 (de)
DK (1) DK0932399T3 (de)
EA (1) EA002400B1 (de)
ES (2) ES2448467T3 (de)
HU (1) HU226646B1 (de)
IL (1) IL126179A (de)
NO (2) NO324461B1 (de)
NZ (1) NZ332234A (de)
PL (1) PL189698B1 (de)
PT (1) PT932399E (de)
SI (1) SI0932399T1 (de)
UA (1) UA68330C2 (de)
WO (1) WO1997033552A1 (de)

Families Citing this family (371)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6179817B1 (en) 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
JP4420472B2 (ja) * 1996-04-15 2010-02-24 旭化成株式会社 薬物複合体
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
EP0966303A2 (de) * 1996-05-01 1999-12-29 Antivirals Inc. Polypeptidkonjugate zum transport von substanzen durch zellmembranen
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
DE19718339A1 (de) * 1997-04-30 1998-11-12 Schering Ag Polymer beschichtete Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
ATE251913T1 (de) 1997-05-21 2003-11-15 Univ Leland Stanford Junior Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
DE19744135C1 (de) * 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US20040170563A1 (en) * 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
PT1041985E (pt) * 1997-12-22 2006-07-31 Schering Corp Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
US6394945B1 (en) * 1997-12-22 2002-05-28 Mds (Canada), Inc. Radioactively coated devices
KR100228187B1 (ko) * 1997-12-24 1999-11-01 김성년 풍선도자 기구에 사용되는 방사성 밸룬 및 그의 제조방법
EP0998934A4 (de) * 1997-12-25 2005-09-14 Toray Industries Heilmittel gegen intramedullare krankheiten
PL201329B1 (pl) * 1998-02-05 2009-03-31 Novartis Ag Preparat farmaceutyczny w postaci koncentratu infuzyjnego
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
US6683100B2 (en) * 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69900689T2 (de) * 1998-06-26 2002-08-29 Quanam Medical Corp Topoisomerase inhibitoren zur restenose-prevention
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6299604B1 (en) 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
AU775875B2 (en) * 1999-01-12 2004-08-19 Quanam Medical Corporation Composition and methods for administration of water-insoluble paclitaxel derivatives
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
AU768527B2 (en) * 1999-02-23 2003-12-18 Angiotech International Ag Compositions and methods for improving integrity of compromised body passageways and cavities
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040121954A1 (en) * 1999-04-13 2004-06-24 Xu Wuhan Jingya Poly(dipeptide) as a drug carrier
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6317615B1 (en) 1999-04-19 2001-11-13 Cardiac Pacemakers, Inc. Method and system for reducing arterial restenosis in the presence of an intravascular stent
JP4343473B2 (ja) * 1999-06-21 2009-10-14 日本メジフィジックス株式会社 血漿蛋白質に結合親和性を有する薬剤の投与方法並びに当該投与方法に用いられる製剤
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6273901B1 (en) 1999-08-10 2001-08-14 Scimed Life Systems, Inc. Thrombosis filter having a surface treatment
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
AU769315B2 (en) 1999-08-24 2004-01-22 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001017508A1 (en) * 1999-09-09 2001-03-15 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
CN1111166C (zh) * 1999-09-10 2003-06-11 云南汉德生物技术有限公司 水溶性三尖杉磷碱聚氨基酸酯或其盐,含它们的药物组合物及其医药用途
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HUP0203123A3 (en) * 1999-10-12 2004-12-28 Cell Therapeutics Inc Seattle Process for preparation of polyglutamate-therapeutic agent conjugates
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001247513A1 (en) * 2000-03-17 2001-10-03 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001253479A1 (en) 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
CA2410906C (en) * 2000-06-02 2012-10-02 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
CN1125097C (zh) * 2000-07-05 2003-10-22 天津大学 聚乙二醇支载的紫杉醇或多烯紫杉醇的前药
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US6612976B2 (en) * 2000-11-13 2003-09-02 Isotech, L.L.C. Radioactive medical devices and methods of making radioactive medical devices
US6616592B1 (en) * 2000-11-13 2003-09-09 Isotech, L.L.C. Radioactive medical devices for inhibiting a hyperplastic response and method of making radioactive medical devices
US20090306228A1 (en) * 2000-11-14 2009-12-10 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
EP1347794A2 (de) * 2000-11-27 2003-10-01 Medtronic, Inc. Stents und verfahren zur herstellung von stents aus drähten mit hydrogel-beschichtung
WO2002049501A2 (en) * 2000-12-18 2002-06-27 Board Of Regents, University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
EP1353659A1 (de) * 2001-01-24 2003-10-22 Mestex AG Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
KR20030071853A (ko) * 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
US7771468B2 (en) * 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
WO2002074042A2 (en) * 2001-03-19 2002-09-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
WO2002090390A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7708712B2 (en) * 2001-09-04 2010-05-04 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in a body organ
CA2458828A1 (en) * 2001-09-24 2003-05-01 James J. Barry Optimized dosing for drug coated stents
CA2464346A1 (en) * 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
US7488313B2 (en) * 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
DE10158904A1 (de) * 2001-11-30 2003-06-12 Roche Diagnostics Gmbh Verfahren zur Herstellung von linearen DNA Fragmenten für die in vitro Expression von Proteinen
KR20030049023A (ko) * 2001-12-13 2003-06-25 주식회사 코오롱 방사선 감작제용 파클리탁셀 유도체
RU2004119557A (ru) * 2001-12-20 2005-04-20 Бристол-Маерс Сквибб Компани (Us) Фармацевтические композиции перорально активных производных таксана с повышенной биодоступностью
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
EP1468036B1 (de) 2002-01-14 2008-10-08 The General Hospital Corporation Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
KR20030068955A (ko) * 2002-02-19 2003-08-25 주식회사 코오롱 새로운 중간 결합체(ｓｅｌｆ-ｉｍｍｏｌａｔｉｎｇｌｉｎｋｅｒ) 화합물과 그 제조방법, 이를 이용한파클리탁셀 또는 이의 유도체의 잔기를 포함하는 수용성프로드럭 화합물, 그의 제조방법 및 이를 유효성분으로포함하는 약제 조성물
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
ES2500117T3 (es) * 2002-02-22 2014-09-30 Shire Llc Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
IL163668A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Use of peptide-drug conjugation to reduce inter-subject variability ofdrug serum levels
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
DE60335608D1 (de) 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
CN100475269C (zh) * 2002-03-05 2009-04-08 北京键凯科技有限公司 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
JP4272537B2 (ja) * 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
WO2003080593A1 (fr) * 2002-03-22 2003-10-02 Beijing Jiankai Technology Co., Ltd. Conjugues hydrophiles de polymeres-flavonoides et compositions pharmaceutiques les contenant
US7264822B2 (en) * 2002-04-03 2007-09-04 Poly-Med, Inc. Conjugated drug-polymer coated stent
JP2006514681A (ja) * 2002-05-20 2006-05-11 コーザン バイオサイエンシス インコーポレイテッド エポチロンｄの投与方法
DK1521603T3 (da) 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
BR0314107A (pt) * 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Método de produção de derivados de hidroxialquil amido
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
US7326421B2 (en) 2002-10-21 2008-02-05 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
ES2336911T3 (es) 2002-11-07 2010-04-19 Kosan Biosciences, Inc. Trans-9,10-dehidroepotilonas c y d, sus analogos y procedimientos de preparacion.
CN101985443A (zh) * 2002-11-07 2011-03-16 得克萨斯大学体系董事会 乙二半胱氨酸（ec）-药物结合物、组合物及用于组织特异性疾病显像的方法
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US20050009849A1 (en) * 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
EP1596825A2 (de) 2003-02-03 2005-11-23 Neopharm, Inc. Stabiles steriles filtrierbares liposom-enkapsuliertes taxan und andere antineoplastische wirkstoffe
US7311727B2 (en) * 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
KR101064901B1 (ko) * 2003-03-20 2011-09-16 나노캐리어 가부시키가이샤 난수용성 항암제와 신규 블록 공중합체를 포함하는 미셀조제물
US7306580B2 (en) * 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
EP1475105A1 (de) * 2003-05-09 2004-11-10 Schering AG Knochengewebegerichtetes Radiopharmaceuticum und Tubulin-interagierende Verbindung kombinatorischer Radiotherapie
TW200427503A (en) * 2003-05-27 2004-12-16 Kureha Chemical Ind Co Ltd Process for producing thermoplastic resin molding
KR101170840B1 (ko) * 2003-05-29 2012-08-03 샤이어 엘엘씨 남용 방지성 암페타민 화합물
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
DE10324710A1 (de) 2003-05-30 2004-12-16 Supramol Parenteral Colloids Gmbh Stärkederivatkomplexe
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
SG145746A1 (en) * 2003-08-08 2008-09-29 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and g-csf
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
WO2005023294A2 (en) 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system
PL1675622T3 (pl) 2003-09-17 2017-11-30 Nektar Therapeutics Proleki na bazie wieloramiennego polimeru
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1675555A4 (de) * 2003-09-30 2011-03-09 Shire Llc Pharmazeutische zusammensetzungen zur prävention einer überdosierung oder von missbrauch
US7790835B2 (en) * 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
ITTO20040056A1 (it) * 2004-02-05 2004-05-05 Sorin Biomedica Cardio Spa Stent per l'erogazione endoliminale di principi o agenti attivi
WO2005092391A2 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005092928A1 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
US7705036B2 (en) 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
CA2561733A1 (en) 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US20080095704A1 (en) * 2004-07-02 2008-04-24 Alan Cuthbertson Imaging Agents with Improved Pharmacokinetic Profiles
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
EP1877097B1 (de) * 2004-08-11 2012-06-20 Arqule, Inc. Konjugate aus beta-lapachon und aminosäuren für tumor-targeting
CN101023119B (zh) 2004-09-22 2010-05-05 日本化药株式会社 新型嵌段共聚物，胶束制剂以及含胶束制剂为活性组分的抗癌剂
MX2007005988A (es) 2004-11-18 2007-07-10 Cardiome Pharma Corp Procedimiento sintetico para compuestos de eter aminociclohexilico.
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
EP2301531B1 (de) 2005-02-18 2018-06-06 Abraxis BioScience, LLC Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
KR20080008364A (ko) * 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
US8574259B2 (en) 2005-05-10 2013-11-05 Lifescreen Sciences Llc Intravascular filter with drug reservoir
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0612138B8 (pt) 2005-06-15 2021-05-25 Cardiome Pharma Corp compostos éter aminocicloexílicos e método para fazer os mesmos
ES2341285T3 (es) * 2005-07-19 2010-06-17 Nektar Therapeutics Metodo para preparar maleimidas polimericas.
JP2009513182A (ja) * 2005-07-21 2009-04-02 エフエムシー バイオポリマー エイエス 急速溶解する生体適合性被覆物で被覆した医療用部材
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
KR101420445B1 (ko) * 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
EP1762250A1 (de) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
US20070167349A1 (en) * 2005-12-06 2007-07-19 Cell Therapeutics, Inc. Estrogen cancer therapy
KR101872061B1 (ko) 2005-12-19 2018-06-27 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US8834912B2 (en) * 2005-12-30 2014-09-16 Boston Scientific Scimed, Inc. Medical devices having multiple charged layers
US7910152B2 (en) * 2006-02-28 2011-03-22 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
JP5249016B2 (ja) * 2006-03-28 2013-07-31 日本化薬株式会社 タキサン類の高分子結合体
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US20090156660A1 (en) * 2006-05-03 2009-06-18 Michal Svoboda Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
KR20090009241A (ko) * 2006-05-18 2009-01-22 니폰 가야꾸 가부시끼가이샤 포도필로톡신류의 고분자 결합체
US20080051603A1 (en) 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
EP1867657A1 (de) 2006-06-15 2007-12-19 Cell Therapeutics Europe S.R.L. Verfahren zur Herstellung von Alpha-Poly(Glutaminsaüre) und seinen Derivaten
CA2656077C (en) 2006-06-15 2014-12-09 Marc Mckennon A process for the preparation of poly-alpha-glutamic acid and derivatives thereof
US20070298069A1 (en) * 2006-06-26 2007-12-27 Boston Scientific Scimed, Inc. Medical devices for release of low solubility therapeutic agents
US8222256B2 (en) * 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
US20090239782A1 (en) * 2006-10-03 2009-09-24 Masaharu Nakamura High-molecular weight conjugate of resorcinol derivatives
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2084310A1 (de) * 2006-10-05 2009-08-05 Boston Scientific Limited Durch plasmaelektrolytische abscheidung gebildete polymerfreie überzüge für medizinische vorrichtungen
EP2080779B1 (de) * 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeres derivat eines nucleinsäuremetabolismus-antagonisten
EP2090607B1 (de) * 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymerderivat eines nukleinsäuremetabolismus-antagonisten
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
KR100847123B1 (ko) * 2006-11-22 2008-07-18 주식회사 스텐다드싸이텍 스텐트
CN101583380B (zh) 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
CN101209350B (zh) 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
CA2743022C (en) 2007-01-21 2012-10-09 Hemoteq Ag Methods for coating catheter balloons with a defined quantity of active agent
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP1967854B8 (de) 2007-03-06 2010-12-29 Cell Therapeutics, Inc. Verfahren zur Bestimmung der Menge konjugierten Taxans in Polyglutaminsäure-Taxan-Konjugaten
US8784866B2 (en) 2007-03-26 2014-07-22 William Marsh Rice University Water-soluble carbon nanotube compositions for drug delivery and medicinal applications
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
WO2008134528A1 (en) * 2007-04-25 2008-11-06 Board Of Regents, The University Of Texas System Anti-cancer agent-hyaluronic acid conjugate compositions and methods
KR20100017483A (ko) 2007-04-30 2010-02-16 아르퀼 인코포레이티드 퀴논 화합물의 하이드록시 설포네이트 및 그 용도
US20080279782A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polymers conjugated with platinum drugs
EP2155253A2 (de) * 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamatkonjugate und polyglutamat-aminosäure-konjugate mit mehreren wirkstoffen
KR20100017540A (ko) * 2007-05-09 2010-02-16 닛토덴코 가부시키가이샤 소수성 화합물 및 폴리아미노산 콘쥬게이트를 포함하는 조성물
US8252361B2 (en) * 2007-06-05 2012-08-28 Abbott Cardiovascular Systems Inc. Implantable medical devices for local and regional treatment
EP2164497B1 (de) 2007-06-11 2018-08-15 Edge Therapeutics Inc. Arzneiabgabesystem zur prävention von zerebralvasospasmus
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
JP5349318B2 (ja) * 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
WO2009070380A2 (en) * 2007-10-03 2009-06-04 William Marsh Rice University Water-soluble carbon nanotube compositions for drug delivery and medical applications
EP2070951A1 (de) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
US20090169480A1 (en) * 2007-12-31 2009-07-02 Industrial Technology Research Institute Dendritic polymers and magnetic resonance imaging contrast agent employing the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
MX2010009670A (es) * 2008-03-06 2010-09-22 Nitto Denko Corp Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
EP2258397B1 (de) * 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymerkonjugat aus einem physiologisch aktiven stoff
CN101569748B (zh) * 2008-04-30 2012-08-22 宁波大学 一种水溶性的紫杉醇的前药制备方法
CN101569747B (zh) * 2008-04-30 2012-08-22 宁波大学 一种聚乙二醇为载体的紫杉醇的前药制备方法
US9126025B2 (en) * 2008-05-01 2015-09-08 Bayer Intellectual Property Gmbh Method of coating a folded catheter balloon
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
JP2011162569A (ja) * 2008-05-23 2011-08-25 Nano Career Kk カンプトテシン高分子誘導体及びその用途
KR20110051214A (ko) * 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
ES2744975T3 (es) 2008-09-23 2020-02-27 Nektar Therapeutics Método de dosificación metronómica con profármacos de camptotecina (p. ej. PEG-Irinotecán)
US8049061B2 (en) 2008-09-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
US8076529B2 (en) 2008-09-26 2011-12-13 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix for intraluminal drug delivery
US8226603B2 (en) 2008-09-25 2012-07-24 Abbott Cardiovascular Systems Inc. Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8500687B2 (en) 2008-09-25 2013-08-06 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US20100111841A1 (en) * 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9040087B2 (en) 2008-10-31 2015-05-26 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
CN102307473A (zh) 2008-12-10 2012-01-04 摩萨纳医疗有限公司 可生物降解的生物相容性喜树碱-聚合物共轭物的药物制剂
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP2431403B1 (de) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymerkonjugat aus einer bioaktiven substanz mit einer hydroxidgruppe
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2944332B1 (de) 2009-07-10 2016-08-17 Boston Scientific Scimed, Inc. Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
WO2011123395A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
DE102010022588A1 (de) 2010-05-27 2011-12-01 Hemoteq Ag Ballonkatheter mit einer partikelfrei Wirkstoff-abgebenden Beschichtung
NZ604031A (en) 2010-06-04 2015-05-29 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
WO2012004009A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
WO2012004007A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
EP2590677A1 (de) 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Konjugate mit hydroxyalkylstärke und einem zytotoxischen mittel sowie verfahren zu ihrer herstellung
EP2591008A1 (de) 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Konjugate mit hydroxyalkylstärke und einem zytotoxischen mittel sowie verfahren zu ihrer herstellung
CN102339813A (zh) 2010-07-14 2012-02-01 中国科学院微电子研究所 半导体结构及其制造方法
EP2611476B1 (de) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Beschichtungsverfahren für wirkstofffreisetzungsballons mit wärmeinduziertem rewrap-gedächtnis
JP5856069B2 (ja) 2010-11-17 2016-02-09 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
BR112013020512A2 (pt) 2011-02-11 2016-09-06 Edge Therapeutics composições e métodos para melhorar o prognóstico de um humano com hemorragia subaracnóide
KR101302703B1 (ko) 2011-02-28 2013-09-03 부산대학교 산학협력단 폴리하이드록시옥타노에이트와 생분해성 고분자의 그라프트공중합체 합성에 의한 약물담지체와 이를 이용한 비혈관계 약물방출형 치료용 스텐트
KR101302698B1 (ko) * 2011-02-28 2013-09-03 부산대학교 산학협력단 폴리하이드록시옥타노에이트와 생분해성 고분자의 블락공중합체 합성에 의한 약물담지체와 이를 이용한 비혈관계 약물방출형 치료용 스텐트.
KR101328660B1 (ko) * 2011-02-28 2013-11-14 부산대학교 산학협력단 항암제 소라페닙을 담지한 폴리카프로락톤 고분자담지체 및 이를 이용한 약물조절 방출형 스텐트
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
ES2558357T3 (es) 2011-06-23 2016-02-03 Dsm Ip Assets B.V. Micro- o nanopartículas que comprenden un copolímero de poliesteramida biodegradable para uso en el suministro de agentes bioactivos
CN102850301A (zh) * 2011-06-28 2013-01-02 中国人民解放军军事医学科学院毒物药物研究所 水溶性紫杉醇衍生物及其药物组合物及其医药用途
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
RU2623426C2 (ru) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Способ получения блок-сополимера
CN103083680B (zh) 2011-11-07 2014-12-24 北京键凯科技有限公司 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
WO2013130684A1 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
WO2013146381A1 (ja) * 2012-03-27 2013-10-03 テルモ株式会社 薬剤コート層およびこれを有する医療機器
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
CN102614110B (zh) * 2012-04-27 2013-12-25 北京大学 稳定的聚乙二醇化药物型胶束组合物及其制备方法
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
CN102702140B (zh) * 2012-06-19 2014-05-14 中国医学科学院生物医学工程研究所 一种水溶性紫杉醇化合物的制备方法及用途
CN102731442B (zh) * 2012-07-18 2014-06-11 中国医学科学院生物医学工程研究所 一种水溶性多烯紫杉醇化合物的制备方法及用途
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
ES2689921T3 (es) 2012-11-30 2018-11-16 Novomedix, Llc Biarilsulfonamidas sustituidas y sus usos
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2014182542A1 (en) 2013-05-06 2014-11-13 Abbott Cardiovascular Systems Inc. A hollow stent filled with a therapeutic agent formulation
CN103263675B (zh) * 2013-05-16 2015-02-11 湘潭大学 一种聚ε-己内酯负载的抗肿瘤前药及其制备方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
CN104721830A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 Top肽
WO2016097297A1 (en) 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
JP2018527287A (ja) * 2015-05-15 2018-09-20 アルブヴェックス エルエルシー ドセタキセルおよびヒト血清アルブミンの複合体
KR101726728B1 (ko) * 2015-07-28 2017-04-14 주식회사 삼양바이오팜 고분자 담체 함유 약학 조성물의 유연물질 분석 방법
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
MX2018002226A (es) 2015-08-28 2018-03-23 Amunix Operating Inc Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo.
CN106554329B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性紫杉醇抗癌药物化合物及其制备方法和应用
CN106554330B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性多西他赛抗癌药物化合物及其制备方法和应用
WO2017193757A1 (zh) * 2016-05-10 2017-11-16 浙江海正药业股份有限公司 水溶性Epothilone衍生物及其制备方法
CN109415378B (zh) * 2016-05-10 2021-11-09 浙江海正药业股份有限公司 水溶性Epothilone衍生物及其制备方法
CN108478804B (zh) * 2018-05-08 2020-09-22 辽宁大学 一种聚丙烯酸-s-s-药物共聚物及其制备方法
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
SG11202107906UA (en) * 2019-01-28 2021-08-30 Univ Texas Metal chelator combination therapy for the treatment of cancer
CN112604002A (zh) * 2020-07-12 2021-04-06 苏州裕泰医药科技有限公司 二硫键桥连的多西他赛-脂肪酸前药及其自组装纳米粒
US20230277490A1 (en) * 2020-07-31 2023-09-07 Cedars-Sinai Medical Center Glutamine as an anticancer therapy in solid tumors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
IN165717B (de) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
JPH069600A (ja) 1992-05-06 1994-01-18 Bristol Myers Squibb Co タクソールのベンゾエート誘導体
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
US5380751A (en) 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
NO310238B1 (no) 1992-12-24 2001-06-11 Bristol Myers Squibb Co Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2154667A1 (en) * 1993-02-02 1994-08-18 Linda M. Gustavson Directed biodistribution of small molecules
WO1994020453A1 (en) * 1993-03-09 1994-09-15 Enzon, Inc. Taxol polyalkylene oxide conjugates of taxol and taxol intermediates
WO1994020089A1 (en) * 1993-03-09 1994-09-15 Enzon, Inc. Taxol-based compositions with enhanced bioactivity
US5468769A (en) 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
DK0797988T3 (da) * 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
WO1995011020A1 (en) * 1993-10-20 1995-04-27 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US5489589A (en) 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5762909A (en) 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses

Also Published As

Publication number Publication date
HU226646B1 (en) 2009-05-28
PT932399E (pt) 2006-05-31
ATE314843T1 (de) 2006-02-15
EA199800817A1 (ru) 1999-04-29
US5977163A (en) 1999-11-02
EP1683520B1 (de) 2013-11-20
CN101028259A (zh) 2007-09-05
IL126179A0 (en) 1999-05-09
KR20000067033A (ko) 2000-11-15
ES2448467T3 (es) 2014-03-14
US6262107B1 (en) 2001-07-17
DE69735057T2 (de) 2006-08-31
EP0932399B1 (de) 2006-01-04
NO324461B1 (no) 2007-10-22
JP2000507930A (ja) 2000-06-27
IL126179A (en) 2003-04-10
HUP9903952A3 (en) 2001-06-28
CA2250295C (en) 2008-12-30
SI0932399T1 (sl) 2006-10-31
EP1683520A2 (de) 2006-07-26
NO332539B1 (no) 2012-10-15
CN1304058C (zh) 2007-03-14
EP0932399A1 (de) 1999-08-04
CZ297979B6 (cs) 2007-05-16
KR100561788B1 (ko) 2006-09-20
PL328807A1 (en) 1999-02-15
BR9710646A (pt) 2000-01-11
DK0932399T3 (da) 2006-05-15
CA2250295A1 (en) 1997-09-18
UA68330C2 (en) 2004-08-16
NZ332234A (en) 2000-06-23
HUP9903952A2 (hu) 2001-05-28
AU735900B2 (en) 2001-07-19
CZ290898A3 (cs) 1999-07-14
NO984210D0 (no) 1998-09-11
PL189698B1 (pl) 2005-09-30
AU2580697A (en) 1997-10-01
WO1997033552A1 (en) 1997-09-18
NO20072562L (no) 1998-11-11
ES2258790T3 (es) 2006-09-01
EP1683520A3 (de) 2009-11-18
EA002400B1 (ru) 2002-04-25
NO984210L (no) 1998-11-11
EP0932399A4 (de) 2002-10-24
CN1217662A (zh) 1999-05-26
JP3737518B2 (ja) 2006-01-18
JP2003063960A (ja) 2003-03-05

Similar Documents

Publication Publication Date Title
DE69735057D1 (de) Wasserlösliche paclitaxel-prodrogen
TW200517105A (en) Pharmaceutical compositions of water soluble docetaxel, etoposide, teniposide, camptothecin or epothilone for the treatment of a tumor
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
DE69730217D1 (de) Dha-pharmazeutisches produkt konjugate
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
DE69911017D1 (en) Arylsulfonanilid-phosphate
AU5111490A (en) Aerosol compositions intended for the imaging, diagnosis and targeted therapy of inflammatory and tumour foci

Legal Events

Date Code Title Description
8364 No opposition during term of opposition